Saad Muntazim

Saad Muntazim is a notable inventor based in New York, NY, with a focus on innovative drug delivery systems. He holds five patents, showcasing his commitment to advancing medical technology and improving patient care.

Latest Patents

One of his latest patents is the oral eliglustat transmucosal delivery system. This invention relates to an oral transmucosal dosage form that comprises a non-disintegrating solid mass. The formulation includes a hydrophilic viscosity modifying agent, a low molecular weight water-soluble component, and a specific amount of eliglustat. The dosage form is designed to be 500 mg or less and provides an oral cavity residence time of at least five minutes. It generates a microenvironment inside the oral cavity that exhibits thixotropic behavior, with viscosities of at least 50 poises at a 1/sec shear rate and at least 10 poises at a 10/sec shear rate. This innovative dosage form allows for at least a 30% dose reduction compared to commercially available eliglustat capsules. Furthermore, it can be administered to patients with Gaucher disease type 1 without the need for pre-determination of the patients' CYP2D6 genotype.

Career Highlights

Throughout his career, Saad Muntazim has worked with various companies, including Abon Pharmaceuticals LLC. His contributions to the field of pharmaceutical sciences have been significant, particularly in the development of oral drug delivery systems.

Collaborations

Saad has collaborated with notable professionals in the industry, including Salah Uddin Ahmed and Yanming Zu. These collaborations have further enhanced his research and development efforts.

Conclusion

Saad Muntazim's innovative work in oral drug delivery systems exemplifies his dedication to improving healthcare solutions. His patents reflect a significant advancement in the treatment of conditions like Gaucher disease, showcasing the impact of his contributions to the field.

This text is generated by artificial intelligence and may not be accurate.